Unigef 250mg Tablet

About

Unigef 250mg Tablet is a targeted therapy belonging to the class of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors, specifically indicated for the treatment of advanced non-small cell lung cancer (NSCLC). Its mechanism of action involves selectively and reversibly blocking the intracellular phosphorylation of tyrosine residues associated with the EGFR. This receptor, when overexpressed or mutated, drives uncontrolled cell growth and survival in many cancers. By inhibiting this critical signaling pathway, Unigef effectively prevents the proliferation, survival, and metastasis of cancer cells. It demonstrates particular efficacy in patients whose tumors harbor specific activating mutations within the EGFR gene, offering a highly personalized therapeutic approach that can lead to significant clinical responses and improved progression-free survival compared to conventional chemotherapy in this distinct patient subgroup.

Uses

• Treatment of advanced non-small cell lung cancer (NSCLC).
• Used in patients with activating EGFR mutations.
• First-line therapy for metastatic NSCLC with EGFR mutations.
• Second-line therapy after failure of platinum-based chemotherapy.

Directions For Use

Take one tablet orally once daily, with or without food, as directed by your doctor. Swallow the tablet whole.

Benefits

• Targets specific EGFR mutations in NSCLC.
• Offers a personalized treatment approach.
• Can lead to significant tumor shrinkage.
• Improves progression-free survival.
• Generally better tolerated than traditional chemotherapy.
• Oral administration for patient convenience.

Side Effects

• Diarrhea
• Skin rash (acneiform dermatitis)
• Dry skin
• Nausea
• Vomiting
• Anorexia
• Stomatitis
• Conjunctivitis
• Elevated liver enzymes
• Interstitial lung disease (rare but serious)
• Fatigue
• Hair changes

Safety Measures

• Alcohol - Moderate alcohol consumption is generally acceptable, but excessive intake may exacerbate liver enzyme elevations.
• Pregnancy - Unigef is contraindicated in pregnancy due to potential fetal harm. Women of childbearing potential should use effective contraception.
• Breastfeeding - Breastfeeding is not recommended during Unigef treatment due to potential harm to the infant.
• Liver - Use with caution in patients with pre-existing liver impairment. Regular monitoring of liver function tests is essential.
• Kidney - Generally considered safe for use in patients with kidney conditions, but caution is advised in severe renal impairment.
• Lung - Monitor closely for new or worsening pulmonary symptoms (e.g., dyspnea, cough, fever) as interstitial lung disease is a rare but serious side effect.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.